Nail changes secondary to docetaxel (Taxotere)

被引：48

作者：

Correia, O ^{[1
]}

Azevedo, C

Ferreira, EP

Cruz, FB

Polónia, J

机构：

[1] Inst Portugues Oncol, Dept Dermatol, P-4200 Oporto, Portugal

[2] Inst Portugues Oncol, Dept Clin Oncol 3, P-4200 Oporto, Portugal

[3] Inst Portugues Oncol, Dept Clin Oncol 4, P-4200 Oporto, Portugal

[4] Fac Med, Dept Immunol, Porto, Portugal

[5] Fac Med, Dept Clin Pharmacol, Porto, Portugal

来源：

DERMATOLOGY | 1999年 / 198卷 / 03期

关键词：

nail; adverse effects; docetaxel; chemotherapy;

D O I：

10.1159/000018132

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Docetaxel is a new taxoid antineoplastic drug widely used for advanced breast cancer. Skin and nail toxicity are one of the more frequent nonhematologic adverse reactions. Besides dark pigmentations and Beau's lines, subungual hemorrhage, orange discoloration, acute painful paronychia, onycholysis, subungual hyperkeratosis and transverse loss of the nail plate are described. The type of nail alteration is related with the number of cycles administered and there are no efficacious preventive measures to avoid its development. Clinicians should recognize the clinical picture of these adverse nail reactions because docetaxel is used for several neoplastic disorders.

引用

页码：288 / 290

页数：3

共 16 条

[1]

BEGAUD B, 1985, THERAPIE, V40, P111

[2] DOCETAXEL (TAXOTERE(R)) - AN ACTIVE-DRUG FOR THE TREATMENT OF PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].

CATIMEL, G ;

VERWEIJ, J ;

MATTIJSSEN, V ;

HANAUSKE, A ;

PICCART, M ;

WANDERS, J ;

FRANKLIN, H ;

LEBAIL, N ;

CLAVEL, M ;

KAYE, SB .

ANNALS OF ONCOLOGY, 1994, 5 (06) :533-537

[3] DOCETAXEL IS A MAJOR CYTOTOXIC DRUG FOR THE TREATMENT OF ADVANCED BREAST-CANCER - A PHASE-II TRIAL OF THE CLINICAL SCREENING COOPERATIVE GROUP OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER [J].

CHEVALLIER, B ;

FUMOLEAU, P ;

KERBRAT, P ;

DIERAS, V ;

ROCHE, H ;

KRAKOWSKI, I ;

AZLI, N ;

BAYSSAS, M ;

LENTZ, MA ;

VANGLABBEKE, M .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) :314-322

[4]

CORREIA O, 1997, AUST J DERMATOL S2, V38, P282

[5]

HUININK WWT, 1994, ANN ONCOL, V5, P527

[6] Nail bed dyschromia secondary to docetaxel therapy [J].

Jacob, CI ;

Patten, SF .

ARCHIVES OF DERMATOLOGY, 1998, 134 (09) :1167-1168

[7]

LOMBARTCUSSAC A, 1997, ARCH DERMATOL, V133, P1466

[8] Onycholysis in patients treated with docetaxel [J].

Obermair, A ;

Binder, M ;

Barrada, M ;

Bancher-Todesca, D ;

Asseryanis, E ;

Kubista, E .

ANNALS OF ONCOLOGY, 1998, 9 (02) :230-231

[9] Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for Research and Treatment of Cancer investigational drug branch for breast cancer [J].

Piccart, MJ ;

Klijn, J ;

Paridaens, R ;

Nooij, M ;

Mauriac, L ;

Coleman, R ;

Bontenbal, M ;

Awada, A ;

Selleslags, J ;

VanVreckem, A ;

VanGlabbeke, M .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) :3149-3155

[10] COPING WITH TOXICITIES OF DOCETAXEL (TAXOTERE(TM)) [J].

SCHRIJVERS, D ;

WANDERS, J ;

DIRIX, L ;

PROVE, A ;

VONCK, I ;

VANOOSTEROM, A ;

KAYE, S .

ANNALS OF ONCOLOGY, 1993, 4 (07) :610-611

← 1 2 →